Oestrogen is simultaneously the hormone most associated with female vitality and the hormone most implicated in female cancer risk. The paradox resolves when you understand that oestrogen operates in a tissue-specific and context-dependent manner — its effects in premenopausal women are fundamentall

Two Faces of the Same Hormone

Oestrogen is simultaneously the hormone most associated with female vitality and the hormone most implicated in female cancer risk. The paradox resolves when you understand that oestrogen operates in a tissue-specific and context-dependent manner — its effects in premenopausal women are fundamentally different from its effects in postmenopausal women on hormone replacement therapy (HRT), and the difference is primarily determined by progesterone exposure and the metabolic context in which oestrogen acts.

The Premenopausal Protective Effect

In premenopausal women with normal ovulatory cycles, oestrogen exerts protective effects on the cardiovascular system — it upregulates HDL cholesterol, downregulates LDL cholesterol, maintains endothelial function, and supports the anti-inflammatory effects of nitric oxide. The cardiovascular protective effect of endogenous oestrogen explains the relatively low cardiovascular disease rates in premenopausal women compared to age-matched men. This protection is not present in anovulatory PCOS women, whose oestrogen exposure is lower and whose metabolic context is different, which is why PCOS is associated with elevated cardiovascular risk despite relatively higher oestrogen levels in some phases.

The bone-protective effect of oestrogen is well-established — oestrogen maintains osteoblast activity and suppresses osteoclast activity, keeping bone resorption in balance with bone formation. The sharp acceleration of bone loss after menopause, when oestrogen levels fall by 80-90%, establishes oestrogen as the primary determinant of female skeletal health across the lifespan. This is the clinical basis for the bone-protective effects of menopausal hormone therapy (MHT) when initiated within 10 years of menopause.

Why Postmenopausal Oestrogen Is Different

The postmenopausal oestrogen effect depends critically on whether oestrogen is administered with progesterone (combined MHT) or alone (oestrogen-only MHT). In women with an intact uterus, oestrogen-only MHT significantly increases endometrial cancer risk — the uterus is exposed to unopposed oestrogen without progesterone’s protective effect on the endometrium. In combined MHT, progesterone is administered concurrently, protecting the endometrium from oestrogen’s proliferative effects.

The breast cancer risk associated with combined MHT — a small but measurable increase in risk — is also modulated by the progesterone component. Oestrogen receptors are present in breast tissue, and oestrogen stimulates breast cell proliferation. Progesterone causes breast cell differentiation, which may reduce the mitogenic stimulus of oestrogen alone. The overall risk-benefit calculation for MHT depends on the individual patient’s risk profile: for women with no personal or family history of breast cancer, no significant cardiovascular risk, and bothersome menopausal symptoms, the quality-of-life benefit of MHT often outweighs the small absolute risk increase.

The Timing Hypothesis

The most important finding in the menopausal hormone therapy literature is the timing hypothesis — MHT initiated within 10 years of menopause and before age 60 has a favourable risk-benefit profile, including potential cardiovascular protection. MHT initiated more than 10 years after menopause is associated with elevated cardiovascular risk, because by then the cardiovascular protective effects of oestrogen are no longer operative and the pro-thrombotic effects of oestrogen dominate. This timing effect is one of the most important clinical considerations in the decision to initiate or continue MHT.